New medication combined with standard treatment for advanced prostate cancer

Plain-English translation of NCT07213674 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a large phase 3 trial testing a new medication called combined with (a standard prostate cancer treatment) in men with advanced prostate cancer that has stopped responding to hormone therapy. The trial will compare how well this new combination works against standard treatment options your doctor might normally choose. Researchers want to see if adding this medication helps people live longer.

Advanced prostate cancer that resists hormone therapy is difficult to treat, and current options have limited effectiveness. Researchers believe this medication might work better when combined with existing treatments, potentially offering hope to patients who need new options.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer that has spread to other parts of your body and is no longer responding to hormone therapy
you have already been treated with one hormone-blocking medication (such as enzalutamide, apalutamide, or darolutamide) and your cancer continued to grow
you have not yet received chemotherapy for your advanced prostate cancer
you have testosterone levels at a castrate level (very low) from previous surgery or ongoing hormone treatment
you are at least 18 years old and in reasonably good overall health

You likely don't qualify if…

you have cancer that has spread to your brain or central nervous system
you have already been treated with this new medication (xaluritamig) before
you previously received chemotherapy (docetaxel or cabazitaxel) for advanced prostate cancer, or received more than 6 rounds of docetaxel for earlier-stage disease
you have ongoing side effects from previous cancer treatments that have not improved to mild levels
you are currently unable to take medications by mouth or have severe organ function problems

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication combined with , or one of three standard treatment options your doctor might choose. You will take these medications on a regular schedule and have follow-up visits to monitor how you are doing through blood tests, imaging scans, and physical exams. The trial involves 750 participants across multiple locations, and researchers will track your health over time to see whether the new combination treatment helps people live longer.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(144 sites)

United States

City of Hope Cancer Center Phoenix, Goodyear, Arizona

City of Hope National Medical Center, Duarte, California

City of Hope Orange County Lennar Foundation Cancer Center, Duarte, California

Providence Saint Jude Medical Center, Fullerton, California

University of California Irvine, Orange, California